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A B ST R AC T 
 
 
The progress made over the past years in the field of cancer therapy 
has led to a significant decrease in cancer mortality, but these 
therapies have many adverse effects, cardiovascular effects being 
among the most frequent ones. For increasing lifelong expectancy of 
surviving cancer patients, cardiac monitoring represents an 
important task. Current studies and practice recommend 
echocardiography using strain analysis for monitoring the cardio 
toxic effects of cancer therapy. The potential of combining imaging 
techniques with biomarkers for the early detection and diagnosis 
seems a promising path for future research.   
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The progress made over the past years in the field of 
cancer therapy has led to a significant decrease in cancer 
mortality. However, these therapies have many adverse 
effects, cardiovascular effects being among the most 
frequent ones. In addition to the fact that they decrease the 
quality of life, they can lead to a reduction in the overall 
survival rate, independently of the prognosis of cancer 
disease [1]. In fact, the term cardiotoxicity refers to 
myocardial dysfunction and heart failure (HF), the most 
redoubtable complications of these therapies, which occur 
in variable proportions, being estimated at 1.7-20.1% for 
trastuzumab and 1.6-4% for bevacizumab [2]. 
Currently, efforts are aimed at the early detection of left 
ventricular dysfunction (LVD) for the initiation of prompt 
treatment, without compromising cancer therapy. Many 
studies investigate the role of biomarkers in the early 
detection of LVD, before this becomes severe enough to 
induce a decrease in the left ventricular ejection fraction 
(LVEF). Among the most studied markers, there are 
cardiac troponins and natriuretic peptides [3]. 
Discussions 
Troponins 
Troponins represent a complex formed by 3 subunits: 
troponin T (cTnT), troponin I (cTnI), and troponin C 
(cTnC). Isoforms T and I have cardiac specificity, while 
cTnC is present in the myocardium as well as in striated 
muscles [4,5]. Most frequently, their measurement is 
performed in case of acute coronary syndrome, being 
essential for the diagnosis and guidance of the therapeutic 
approach [6]. However, any myocardial lesion, regardless 
of its mechanism of occurrence, which induces myocyte 
membrane damage, also induces intracellular depletion of 
troponins and its subsequent release into the blood [7-11]. 
Drugs that induce progressive/chronic myocardial injury 
cause a small but persistent increase in troponins, which is 
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directly proportional to the duration of the therapy [12-16]. 
Many studies investigate their utility in LVD screening in 
cancer patients. For this review, 16 studies have been 
analyzed. Their characteristics and the main results 
obtained are summarized below (Table 1) [17-22]. 
All studies included samples of patients with HER-
positive breast carcinoma. One study [7] included patients 
who did not receive anthracycline prior to trastuzumab 
therapy. 
Regarding the patients sequentially treated with 
anthracyclines and trastuzumab, studies report divergent 
results. Some authors consider that increased or detectable 
troponin values observed during the treatment with 
trastuzumab might be the result of anthracycline toxicity 
because they occur shortly after the initiation of 
trastuzumab therapy and subsequently tend to normalize 
[8,11,12,21]. A possible explanation could be the different 
cardiotoxicity mechanisms of the two groups of drugs [23]. 
 
Table 1. The characteristics and the main results of the studies investigating cardiac troponin modifications in 
HER2+ breast cancer patients treated with trastuzumab 
Study (year) Troponin 
type 
Troponin measurement Main results 
Ponde N et al. (2018) [7] cTnT1 Baseline, 2 wks2 
18 wks 
2.9% elevation at 18 wks 
Zardavas et al. (2017) [8] us-cTnI3 
hs-cTnT4 
Baseline, 13,25,52 weeks 
18,24,30 mo 
No significant increase; high troponin levels 
at baseline are predictive of LVEF drop5  
Goel S et al. (2011) [9] cTnI Before and 24h after  No troponin elevation 




High hs-cTnI levels at 3 mo predictive of 
cardiotoxicity at 6 mo 
Sawaya H et al. (2012) 
[11] 
us-cTnI Baseline, every 3 mo 
during treatment 
Elevated usTnI concentrations at 3 mo are 
predictive of subsequent cardiotoxicity 
Ky B et al. (2014) [12] cTnI Baseline 3,6 mo Values at 3 mo predictive of cardiotoxicity 
(HR=1.36; p=0.012) 
Changes in TnI values from baseline 
compared to 3 mo are predictive of 
cardiotoxicity (HR8=1.38; p=0.02) 




No increases over time 
Putt M. et al. (2015) [14] hs-cTnI Baseline 
3,6,9,12,15 mo 
 
Maximum hs-cTnI values at 6 mo (12x 
baseline value) 
Not predictive for concurrent (p=0.30) or 
subsequent cardiotoxicity (p=0.14) 
Kitayama H et al. (2017) 
[15] 
hs-cTnT Baseline 
Every 3 to 6 mo 
Patients with cardiotoxicity had elevated hs-
cTnT values 
Stable troponin values in patients without 
cardiotoxicity 
Katsurada K 





Maximum hs-cTnT levels at 3 and 6 mo 
hs-cTnT changes at 6 mo correlate with 
LVEF drop at 15 mo (r = -0.56, p < 0.05) 
Mokuyasu S et al. (2015) 
[17] 
hs-cTnI  8.9% of anthracycline treated patients and 
3% of trastuzumab treated patients had hs-
cTnI elevations 
Onitilo AA et al. (2012) 
[18] 
cTnI Baseline; every 3 wks up 
to 1 year 
No elevations  
Morris PG et al. (2015) 
[19] 
cTnI Every 2 wks during ChT 
and then at 6,9,18 mo 
Detectable cTnI at 2 weeks after 
anthracycline  
Detectable cTnI before maximum LVEF 
drop but not an independent predictive factor  
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Maximum values of hs-cTnT at 3 wks after 
anthracycline treatment 
 
Cardinale D et al. (2010) 
[21] 
cTnI Every 1-3 wks cTnI strongest independent predictive factor 
for cardiotoxicity (HR=17.6; p=0.001) 
patients with high cTnI who develop HF9 are 
less likely to recover despite the treatment 
(HR=2.88; p<0.001) 
Dhir V et al. (2019) [22] hs-TnI Before trastuzumab  No correlations between with LVEF drop 
cTnT1 – troponin T; wks2 - weeks; us -cTnI3 – ultra-sensitive troponin I; hs-cTnT4 – high-sensitive troponin T; 
LVEF5 - ; hs-cTnI6 – high-sensitive troponin I; mo7 - months; HR8 – hazard ratio; HF9 – heart failure 
For example, Mokuyasu et al. [17] compared cTnI 
values in patients treated with anthracyclines and patients 
treated with trastuzumab. The results show that 8.9% of the 
patients who were also treated with anthracyclines had an 
increase in cTnI values compared to 3% of the patients 
treated with trastuzumab. The patients who received no 
anthracyclines did not have increased hs-cTnI values. 
Zardavas et al. [8] demonstrated that in patients with 
high cTn values, these were already present before the 
initiation of the therapy with trastuzumab and did not 
increase significantly afterwards, and that these patients 
had a 2.4-4.5 times higher risk of a decrease in LVEF. 
Similarly, Sawaya et al. [11] showed that the highest us-
cTnI values were recorded shortly after the completion of 
the treatment with anthracyclines, followed by their 
decrease during trastuzumab therapy. According to this 
study, us-cTnI measurement after the completion of 
anthracycline treatment has a sensitivity of 48% and a 
specificity of 73% as a predictor of subsequent 
cardiotoxicity. The usefulness of troponins I as a 
prognostic marker of cardiac dysfunction was also 
demonstrated in the study conducted by Ky B et al. [12]. 
The study carried out by Cardinale et al. [21] also 
reported increased troponin values in the majority of the 
patients (23 of the 36 patients with increased values) at the 
beginning of the treatment with trastuzumab, with their 
normalization over the following 3 months. In addition, the 
authors showed that cTnI values represent the strongest 
independent predictor of cardiotoxicity. Furthermore, the 
authors indicated that patients with high troponin levels 
who develop cardiotoxicity have lower chances of LVEF 
recovery compared to patients with normal cTnI values 
(36% vs. 100%) under optimal medical treatment. 
The study performed by Katsurada K et al. [16] showed 
that hs-cTnT values at 6 months represent a predictive 
factor of the 10% LVEF reduction at 15 months, suggesting 
that this would be a more useful marker than hs-cTnI. A 
more recent study [20, 23] also demonstrated the predictive 
value of hs-cTnT at 3 weeks after the treatment with 
anthracyclines regarding the trastuzumab-induced 
decrease in LVEF. 
In some studies, [14,19], despite an increase in the 
troponin values recorded during treatment, the authors 
could not demonstrate their predictive value in the early 
detection of cardiotoxicity. On the other hand, there are 
studies in which the increase in troponins during therapy 
was not demonstrated [9,13,18,22].  
The only study comprising patients treated exclusively 
with trastuzumab [7] suggests that high troponin values 
occur in a small number of patients and their measurement 
is not useful for monitoring trastuzumab-induced 
cardiotoxicity, but it should be taken into consideration that 
the small sample and the reduced number of cardiac events 
did not allow statistical analysis. 
In conclusion, although there are many studies that 
show the usefulness of troponin measurement for the early 
detection of cardiac toxicity or for the identification of 
patients at risk of developing HF during the therapy with 
trastuzumab after anthracycline treatment, further studies 
with larger samples and standardized measurement 
methods are required for the implementation of this method 
in clinical practice. Comparing the results is difficult since 
different cut-off values for troponin as a marker of 
cardiotoxicity have been chosen. Moreover, troponin 
measurement presents a high variability because of the 
different assays that are used. The imprecision of a typical 
troponin assay that was used in the past was between 10-
20% at the 99th percentile. The new hs-assays managed to 
lower this imprecision below 10% [24]. 
Brain Natriuretic Peptide 
The family of natriuretic peptides includes the atrial 
natriuretic peptide, brain natriuretic peptide (BNP), and C-
type natriuretic peptide (a peptide secreted by the vascular 
endothelium). BNP is released mainly by atrial myocytes 
under normal conditions, and by ventricular myocytes in 
the presence of congestive HF. Thus, increased BNP values 
are the hallmark of ventricular dysfunction. The precursor 
pre-proBNP is cleaved into the biologically active BNP 
molecule and the inactive N-terminal proBNP (NT-
proBNP) fragment. In patients with HF, BNP is more 
increased than the atrial natriuretic peptide and has a half 
higher half-life (20 min vs. 2 min), while NT-proBNP has 
the highest half-life (approximately 120 min) and thus 
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persists more in circulation [25]. BNP values are under the 
influence of several factors. Higher BNP values are seen in 
older patients (the cut-off point for HF jumps from 450 to 
900 pg/ml in patients over 50 years) and in females, but 
obesity leads to significantly lower BNP. Cut-off points for 
diagnosing HF need to be higher if the estimated 
glomerular filtration rate is lower than 60 mL/min/1.73 m2 
[25,26]. 
The widespread use of BNP in clinical practice has led 
to its study in various chemotherapy regimens. In 
anthracycline-based therapy, LVD, symptomatic HF, or 
acute coronary syndrome were associated with BNP values 
above 100 pg/mL. NT-proBNP elevations correlate with 
diastolic and systolic dysfunction after high dose 
chemotherapy [27,28]. 
So far, studies have not shown a useful role for 
BNP/NT-proBNP monitoring during trastuzumab 
treatment. This might be explained by the low 
cardiotoxicity of trastuzumab compared to anthracyclines 
and the difference in assays and cut-off values used in 
various studies [28]. Table 2 provides a summary of the 
results [8-11,13,14,18,20,29-34]. Studies have not looked 
specifically for the influence of bevacizumab therapy on 
BNP in breast cancer patients. Two to four percent of the 
subjects on bevacizumab treatment develop LVD that 
associates increased BNP levels [35]. 
 
Table 2. NT-proBNP1/BNP2 changes during the trastuzumab treatment 
Study (year) NT-proBNP/BNP measurement Main results 
Zardavas et al. 
(2016) [8] 
baseline; wks3 13,25,52; mo4  
18,24,30,36 
Elevated NT-proBNP does not predict a significant 
LVEF5 drop 
Goel et al. 
(2011) [9] 
baseline, after 24 hours No significant change in NT-proBNP 
Sawaya et al. 
(2011) [10] 
baseline, 3 and 6 mo Changes in NT-proBNP do not predict cardiac 
toxicity 
Sawaya et al. 
(2012) [11] 
baseline; 3,6,9,12,15 mo No association between NT-proBNP and cardiac 
toxicity 
Fallah-Rad et 
al. (2011) [13] 
before anthracycline and 
trastuzumab; 3 wks after the final 
cycle; 12 mo after trastuzumab 
No difference between the patients who developed 
cardiomyopathy and those who did not 
Putt et al. 
(2015) [14] 
baseline; 3,6,9,12,15 mo No significant increase in NT-proBNP 
Onitilo et al. 
(2012) [18] 
baseline; every 3 wks up to a year No difference in NT-proBNP associated with a 
LVEF3 drop 
de Vries 
Schultink et al. 
(2018) [20] 
before anthracycline, baseline 
before trastuzumab, up to 92 wks 
after trastuzumab  
Prior treatment with anthracyclines followed by 
trastuzumab does not elevate NT-proBNP 
Advani et al. 
(2017) [29] 
at baseline, days 1,2,3, and 7 during 
1st and 2nd cycle 
Transient increase in NT-proBNP in the first two 
days of the second cycle 
Yu et al. (2016) 
[30] 
baseline 6,12,18,24 and 30 wks No significant increase in BNP 
El-Sherbeny et 
al. (2019) [31] 
baseline 3,6,9 and 12 mo No significant increase in NT-proBNP  
Şendur et al. 
(2015) [32] 
at 9 and 52 wks No difference in NT-proBNP after the treatment; 
cardiac toxicity associated higher NT-proBNP  
Matos et al. 
(2016) [33] 
baseline, after 4,8,12 mo during 
trastuzumab  
No significant difference between patients with and 
without a LVEF drop 
Grover et al. 
(2013) [34] 
baseline and 4 mo No difference in NT-proBNP after anthracyclines or 
trastuzumab 
NT-proBNP1 - N-terminal pro-hormone brain natriuretic peptide; BNP2 - brain natriuretic peptide; wks3 – weeks; 
mo4 – months; LVEF5 – left ventricular ejection fraction 
            




Galectins are β-galactoside-binding lectins with at least 
one carbohydrate recognition domain. There are 15 types 
of galectins, distinguished from one another by the type of 
carbohydrate recognition domain. Galectin-3 is involved in 
numerous cellular processes such as cellular 
differentiation, inflammation, fibrosis, and angiogenesis. 
Cardiovascular diseases such as HF, ischemic heart 
disease, atrial fibrillation, and renal dysfunction are 
associated with increased serum galectin-3 values. At the 
same time, breast tumor tissue has an increased expression 
of galectin-3, and triple negative breast cancer expresses 
more galectin-3 than other types of breast cancer [36]. 
Patients with breast cancer have higher serum galectin-
3 levels compared to healthy subjects (18.41 ng/mL in 
cancer patients and 6.73 ng/mL in controls (p<0.0001). 
After 3 and 6 months of trastuzumab, anthracycline and 
taxane treatment, galectin-3 levels were increased 
compared to baseline. At the same time, HER2- patients 
had higher galectin-3 values than HER2+ patients [37]. In 
contrast, in another study, galectin-3 levels did not increase 
from baseline after 15 months of trastuzumab, doxorubicin, 
and paclitaxel treatment [14]. 
Echocardiographic markers of cardiac dysfunction  
Advances in cancer treatment over the last decades 
have remarkably improved the survival rates of patients 
diagnosed with solid and hematologic malignancies.  
Unfortunately, several chemotherapeutic agents (e.g., 
trastuzumab, bevacizumab) are known to have cardio toxic 
effects [37]. Ventricular dysfunction and heart failure, as a 
complication of cancer therapy, have become major public 
health concerns, as they are associated with poor prognosis 
and long-term morbidity and mortality [38]. The 
development of a subclinical left ventricular dysfunction 
(cancer therapy–related cardiac dysfunction [CTRCD]), 
defined by a threshold change in LV ejection fraction 
(LVEF), may be seen in up to 42% of the patients with 
cancer in selected treatment groups [39]. 
Therefore, the early diagnosis and control of cancer 
therapy-related cardiac dysfunction CTRCD is of crucial 
importance in patients undergoing therapies. In the absence 
of robust risk prediction models, cardiologists are very 
interested in the use of more sensitive markers to detect 
early myocardial dysfunction [40], for CTRCD prevention.  
The most frequent echocardiographic markers used in 
cancer patients are as follows: LVEF by 2D TTE; VTI: 
lateral S wave in both LV and RV; DTI: the detection of 
strain (GLS versus GCS versus GRS) and free wall RV 
strain. 
One of the conventional methods for monitoring 
cardiac function in patients receiving cancer therapy is the 
determination of 2D left ventricular ejection fraction 
(LVEF) with serial transthoracic echocardiography (TTE). 
A value <53% of LVEF or a decrease >10% in LVEF 
during cancer treatment is consistent with cardiac systolic 
dysfunction [41].  
 However, this strategy fails to detect early subtle 
alterations in LV systolic function, as LVEF is dependent 
on hemodynamic conditions. Tissue velocity imaging 
(TVI) and strain imaging are novel, sensitive, non-invasive 
echocardiographic techniques that allow the early 
detection of LV systolic dysfunction, before a decrease in 
conventional LVEF [42]. Tissue velocity imaging has been 
validated in murine models of chemotherapy-induced 
cardiac dysfunction [43] and more recently, evaluated in 
the clinical setting of trastuzumab-induced cardiac 
dysfunction [13]. Neilan et al. demonstrated that a decrease 
in LVEF, detected by conventional echocardiographic 
measures (2D LVEF), was observed on day 5 in mice 
treated with chemotherapy, whereas DTI indices, such as S 
wave maximal velocity, dropped significantly earlier, on 
day 2. These findings were corroborated by Jassal et al. 
[44] in a study conducted in 2009, in which DTI parameters 
decreased within 24 hours in mice treated with doxorubicin 
plus trastuzumab, while a decreased LVEF was observed 
only on day 4. 
In the echocardiographic assessment of both left and 
right ventricular inotropy, tissue Doppler measures, such 
as S or E wave maximal velocities, can be used to quantify 
regional systolic and diastolic function with greater 
accuracy than conventional measures such as LVEF or RV 
FAC [45]. However, we should acknowledge that systolic 
velocities, being Doppler derived measures, are angle-
dependent. Thus, a good alignment of the Doppler 
interrogation line with the region of interest is mandatory 
in order to obtain the correct peak velocities. Nonetheless, 
peak systolic tissue Doppler velocities can be affected by 
the overall motion of the heart and the afterload pressures, 
particularly in the RV [46].  Several investigators have 
demonstrated an early reduction in lateral E velocity of the 
mitral annulus in patients receiving anthracyclines [47] but 
not trastuzumab, which remained reduced during the 
treatment and for several years thereafter. In a study by 
Negishi et al., [48] a 10% reduction in E velocity was 
observed in patients who developed CTRCD. 
Nevertheless, the reduction was neither statistically 
significant nor predictive of subsequent reduction in 
LVEF. In a recent study concerning the RV dysfunction, 
Keramida et al. [49] showed a global and uniform effect of 
trastuzumab on myocardial function, affecting both the left 
and right ventricles. The RV dysfunction was 
demonstrated by a decrease in both TAPSE and S wave, 
criteria of an abnormal longitudinal function. Both 
techniques (M-mode echography and Doppler tissue 
imaging) are angle-dependent, but also load-dependent. 
Among the measures of myocardial function, 
echocardiography-measured peak systolic global 
longitudinal strain (GLS) is the most extensively studied 
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marker and it provides an easy, inexpensive, and 
quantitative assessment of the global long-axis systolic 
function [50]. As a general idea, strain is defined as a 
percentage change in myocardial deformation and strain 
rate as the speed of deformation of myocardial segments. 
Neither the strain nor the strain rate derived parameters 
represent pure myocardial contractility, and none of them 
is load-independent [51,52]. Several studies have linked 
threshold changes in GLS or an absolute GLS value during 
cancer treatment with the subsequent development of 
CTRCD [11]. However, the greatest limitation is that these 
studies differ in the GLS cut-off values, depending on the 
vendors used and the populations studied. The cardio-
oncology expert consensus document of the American 
Society of Echocardiography (ASE) and the European 
Association for Cardiovascular Imaging (EACVI) 
recommends the routine use of GLS in monitoring patients 
during cancer therapy whenever possible. In patients with 
available baseline strain measurements, a relative 
percentage reduction in GLS of less than 8% is not 
meaningful, whereas a change greater than 15% is likely to 
indicate subclinical LV dysfunction (2,52). GLS 
measurements based on 3 apical views is the preferred 
technique for the detection of cardiotoxicity, according to 
Thavendiranathan et al., even though single view LS is less 
time consuming [53]. 
Longitudinal strain seems to be affected when 
cardiotoxicity occurs. Bergamini et al. demonstrated that 
2D GLS was the only parameter significantly modified 
across the studies after 12 months, while, overall, 2D GCS 
was not significantly reduced. Concerning the 2D GRS, the 
analysis demonstrated a significant reduction of this 
parameter, but not all the involved studies showed a 
coherent result after the same follow-up period [54].  
Given the established prognostic significance of the RV 
dysfunction [55] for the outcome of the patients with heart 
failure, the finding of concurrent RV impairment at the 
time of diagnosis of LV cardiotoxicity makes RV GLS a 
useful measurement during trastuzumab therapy. In the 
recent study performed by Keramida et al., in patients 
treated with trastuzumab, the RV FWLS (free wall 
longitudinal strain) changes were modest. On the other 
hand, the insignificant change of RV FWLS raises the 
possibility that the detected impairment of RV GLS is 
attributed mainly to the intraventricular septum that both 
ventricles share. Also, the optimal cut-off value of the 
relative percent change in the RV GLS to predict 
cardiotoxicity was ≥14.8%, almost identical to the 
established LV GLS cut-off. We should also point out that 
both RV GLS and RV FWLS are size-independent 
estimates of contraction, as opposed to peak S velocity and 
TAPSE. But all the parameters proposed to detect early 
changes in RV systolic function are load-dependent; 
therefore, the presence of pulmonary hypertension may 
affect them [56]. 
Data concerning bevacizumab-related cardiotoxicity 
are scarce in the literature, but the same echocardiographic 
markers as for trastuzumab are proposed in the follow-up 
of patients, while the myocardial dysfunction induced 
seems reversible [57]. 
To conclude, the most sensitive marker of the early 
myocardial dysfunction in patients during and after the 
chemotherapy treatment with either trastuzumab or 
bevacizumab is global longitudinal strain GLS, having an 
important prognostic value in the development of end-
stage HF [58]. 
Abbreviations 
BNP - brain natriuretic peptide 
ChT –chemotherapy 
cTnC - troponin C 
cTnI - troponin I 
cTnT - troponin T 
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DTI - One-dimensional tissue Doppler 
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hs-cTnI - high-sensitive troponin I 
hs-cTnT - high-sensitive troponin T 
LV - left ventricle 
LVD - left ventricular dysfunction 
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NT-proBNP - N-terminal pro-hormone brain 
natriuretic peptide 
RV - right ventricle 
RVD - right ventricular dysfunction 
us-cTnI - ultra-sensitive troponin I 
Conclusions 
To conclude, the most sensitive marker of the early 
myocardial dysfunction in patients during and after the 
chemotherapy treatment with either trastuzumab or 
bevacizumab is global longitudinal strain GLS, having an 
important prognostic value in the development of end-
stage HF [58].  
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